Integra LifeSciences Q2: GAAP loss $0.16/sh, adj EPS $0.63; cuts FY2024 guidance on compliance holds

INTEGRA LIFESCIENCES HOLDINGS CORP

2024-Q2 EPS reported -$0.20 revenue$787,047,000

GAAP net loss $12.4M (-$0.16 diluted) vs prior year income $4.2M ($0.05). Adjusted EPS $0.63 vs $0.71.
Revenue $418.2M, up 9.7% reported, 2.3% organic; organic ex-Boston +0.3%. Adjusted gross margin 65.2% (down from 67.6%).
Codman Specialty Surgical rev $301.8M (+11.3% reported, +0.9% organic). Tissue Technologies $116.4M (+5.6% reported, +5.7% organic; -1% ex-Boston).
FY2024 guidance cut: revenue $1.609-1.629B, adjusted EPS $2.41-2.57. Cites temporary shipping holds and investments in quality/GMP compliance.
Received PMA approvable for SurgiMend pending GMP certification; Braintree facility operational readiness expected H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.